Maria-Jimena Muciño-Bermejo
Maria-Jimena Muciño-Bermejo
The concept of extracorporeal organ support (ECOS) encompasses kidney, respiratory, cardiac and hepatic support. In an era of increasing incidence and survival of patients with single or multiple organ failure, knowledge on both multiorgan ...
Case Report: Thromboelastography for uremic thrombocytopathy in a patient with COVID-19 [0.03%]
案例报告：血栓弹力图在COVID-19患者尿毒症性血小板病中的应用
Lakshmi Kannan,Rishi Raj
Lakshmi Kannan
Uremia causes several biochemical and physiological impairments that result in the accumulation of toxins with multiple clinical effects. Bleeding is one of the most common complications of acute and chronic renal failure. The pathogenesis ...
Social determinants and chronic kidney disease of undetermined origin in childhood: Its communication and understanding described by families in Lake Chapala, Mexico [0.03%]
墨西哥查帕拉湖地区儿童慢性肾病的社会决定因素及其家庭沟通和理解
Norma Guadalupe Ruiz-Velazco,Felipe de Jesús Lozano-Kasten,Horacio Guzman-Torres et al.
Norma Guadalupe Ruiz-Velazco et al.
This work is based on the recognition of the existence of a complex relationship between social and environmental determinants and infants with chronic kidney disease of non-traditional etiology (CKDnT). The aim is to understand how the Soc...
Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan [0.03%]
托伐普坦治疗的东北英格兰地区常染色体显性遗传多囊肾病（ADPKD）患者的预后情况分析
Eleftherios Gkekas,Tsz Yau Tiffany Tang,Alan Green et al.
Eleftherios Gkekas et al.
Autosomal dominant polycystic kidney disease (ADPKD) is a cause of end-stage kidney disease (ESKD). The vasopressin V2-receptor antagonist tolvaptan has been shown within randomized clinical trials to slow down decline of kidney function in...
Modifiable Risk Factors Are Important Predictors of COVID-19-Related Mortality in Patients on Hemodialysis [0.03%]
可改变的风险因素是血液透析患者预测新冠肺炎相关死亡的重要指标
Jeroen Peter Kooman,Paola Carioni,Vratislava Kovarova et al.
Jeroen Peter Kooman et al.
Introduction: Patients with end-stage kidney disease face a higher risk of severe outcomes from SARS-CoV-2 infection. Moreover, it is not well known to what extent potentially modifiable risk factors contribute to mortali...
SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist [0.03%]
钠-葡萄糖协同转运蛋白2抑制剂：肾脏病治疗的广谱新药选项
Antonio Granata,Francesco Pesce,Massimo Iacoviello et al.
Antonio Granata et al.
Since their introduction as antidiabetic drugs, SGLT2 inhibitors (SGLT2i) have come a long way, proving to be beneficial on cardiovascular and renal outcomes independently of diabetes status. The benefits go far beyond glycemic control, and...
Harnessing the Full Potential of Multi-Omic Analyses to Advance the Study and Treatment of Chronic Kidney Disease [0.03%]
充分挖掘多组学分析的潜力以促进慢性肾脏疾病的研究和治疗
Claire Hill,Ione Avila-Palencia,Alexander Peter Maxwell et al.
Claire Hill et al.
Chronic kidney disease (CKD) was the 12th leading cause of death globally in 2017 with the prevalence of CKD estimated at ~9%. Early detection and intervention for CKD may improve patient outcomes, but standard testing approaches even in de...
Levels of Soluble NKG2D Ligands and Cancer History in Patients Starting Hemodialysis [0.03%]
开始血液透析患者可溶性NKG2D配体水平与癌症史的关系
Kei Nagai,Takashi Tawara,Joichi Usui et al.
Kei Nagai et al.
Background: Immune dysfunction in hemodialysis patients is partially due to NK cell impairment. Ligands for NK activating receptors such as NKG2D expressed on cancer cells are involved in NK cell dysfunction and can lead ...
SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules [0.03%]
钠葡萄糖协同转运蛋白2抑制剂在2型心肾综合征治疗中的作用：侧重肾脏管腔方面的作用
Yajiao Wang,Xinxin Mao,Shuqing Shi et al.
Yajiao Wang et al.
The pathogenesis of type 2 cardiorenal syndrome (CRS) is mostly associated with reduced cardiac output, increased central venous pressure (CVP), activation of the renin-angiotensin-aldosterone system (RAAS), inflammation, and oxidative stre...
Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge [0.03%]
免疫检查点抑制剂相关肾毒性：临床病理特征、非侵入性方法及治疗策略和再次使用的新进展
Jing Miao,Meghan E Sise,Sandra M Herrmann
Jing Miao
Immune checkpoint inhibitors (ICIs) are used increasingly to treat more than 17 cancers and have shown promising therapeutic results. However, ICI use can result in a variety of immune-related adverse events (IRAEs) which can occur in any o...